4.5 Review

Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Clinical Neurology

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease

Aaron H Burstein et al.

BMC Neurology (2014)

Article Clinical Neurology

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

Douglas Galasko et al.

NEUROLOGY (2014)

Article Medicine, General & Internal

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Stephen Salloway et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Article Clinical Neurology

Amyloid-β and Tau The Trigger and Bullet in Alzheimer Disease Pathogenesis

George S. Bloom

JAMA NEUROLOGY (2014)

Review Clinical Neurology

The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy

Patrick L. McGeer et al.

ACTA NEUROPATHOLOGICA (2013)

Article Clinical Neurology

Alzheimer disease in the United States (2010-2050) estimated using the 2010 census

Liesi E. Hebert et al.

NEUROLOGY (2013)

Article Medicine, Research & Experimental

A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease

Rashid Deane et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

Article Clinical Neurology

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

Marwan N. Sabbagh et al.

ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2011)

Review Geriatrics & Gerontology

Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease

Velandai Srikanth et al.

NEUROBIOLOGY OF AGING (2011)

Review Oncology

The sour side of neurodegenerative disorders: the effects of protein glycation

Hugo Vicente Miranda et al.

JOURNAL OF PATHOLOGY (2010)

Review Medicine, General & Internal

MECHANISMS OF DISEASE Alzheimer's Disease

Henry W. Querfurth et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Review Biochemistry & Molecular Biology

Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease

Ling Zhang et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2009)

Article Neurosciences

Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease

Miles C. Miller et al.

BRAIN RESEARCH (2008)

Article Clinical Neurology

Evidence for Altered LRP/RAGE Expression in Alzheimer Lesion Pathogenesis

Brian Jeynes et al.

CURRENT ALZHEIMER RESEARCH (2008)

Review Pharmacology & Pharmacy

The role of the cell surface LRP and soluble LRP in blood-brain barrier a clearance in Alzheimer's Disease

R. Deane et al.

CURRENT PHARMACEUTICAL DESIGN (2008)

Review Pharmacology & Pharmacy

Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease

Masayoshi Takeuchi et al.

CURRENT PHARMACEUTICAL DESIGN (2008)

Article Clinical Neurology

RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease

John E. Donahue et al.

ACTA NEUROPATHOLOGICA (2006)

Article Biochemistry & Molecular Biology

RAGE potentiates Aβ-induced perturbation of neuronal function in transgenic mice

O Arancio et al.

EMBO JOURNAL (2004)

Article Biochemistry & Molecular Biology

RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

R Deane et al.

NATURE MEDICINE (2003)